BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

578 related articles for article (PubMed ID: 7673013)

  • 1. Patterns of failure following high-dose chemotherapy and autologous bone marrow transplantation with involved field radiotherapy for relapsed/refractory Hodgkin's disease.
    Mundt AJ; Sibley G; Williams S; Hallahan D; Nautiyal J; Weichselbaum RR
    Int J Radiat Oncol Biol Phys; 1995 Sep; 33(2):261-70. PubMed ID: 7673013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose therapy and autologous bone marrow transplantation for Hodgkin's disease patients with relapses potentially treatable by radical radiation therapy.
    Pezner RD; Nademanee A; Forman SJ
    Int J Radiat Oncol Biol Phys; 1995 Aug; 33(1):189-94. PubMed ID: 7642418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [High-dose chemotherapy and autologous stem cell transplantation for refractory and relapsing Hodgkin's disease as first-line therapy-- studies at Sheba Medical Center--Tel Hashomer].
    Avigdor A; Hardan I; Shpilberg O; Raanani P; Grotto I; Ben-Bassat I
    Harefuah; 2000 Sep; 139(5-6):174-9, 248, 247. PubMed ID: 11062945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of involved-field radiotherapy preceding autologous stem cell transplantation for patients with high-risk lymphoma or Hodgkin's disease.
    Dawson LA; Saito NG; Ratanatharathorn V; Uberti JP; Adams PT; Ayash LJ; Reynolds CM; Silver SM; Schipper MJ; Lichter AS; Eisbruch A
    Int J Radiat Oncol Biol Phys; 2004 May; 59(1):208-18. PubMed ID: 15093918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does the addition of involved field radiotherapy to high-dose chemotherapy and stem cell transplantation improve outcomes for patients with relapsed/refractory Hodgkin lymphoma?
    Kahn S; Flowers C; Xu Z; Esiashvili N
    Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):175-80. PubMed ID: 20732769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salvage chemotherapy with mini-BEAM for relapsed or refractory Hodgkin's disease prior to autologous peripheral blood stem cell transplantation.
    Fernández-Jiménez MC; Canales MA; Ojeda E; de Bustos JG; Aguado MJ; Hernández-Navarro F
    Haematologica; 1999 Nov; 84(11):1007-11. PubMed ID: 10553161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What is the optimal treatment volume in Hodgkin's disease patients undergoing high-dose chemotherapy and adjuvant radiation therapy?
    Mundt AJ; Connell PP; Mansur DB
    Radiat Oncol Investig; 1999; 7(6):353-9. PubMed ID: 10644058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of cytoreductive therapy prior to high dose treatment with autologous bone marrow transplantation in relapsed and refractory Hodgkin's disease.
    Brandwein JM; Callum J; Sutcliffe SB; Scott JG; Keating A
    Bone Marrow Transplant; 1990 Feb; 5(2):99-103. PubMed ID: 2310878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of relapsed and refractory Hodgkin's disease with high dose chemotherapy and autologous bone marrow transplantation.
    Brice P; Gisselbrecht C; Ferme C; Lepage E; Baruchel A; Marolleau JP; Gerota O; Boiron M
    Nouv Rev Fr Hematol (1978); 1991; 33(3):267-72. PubMed ID: 1956765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [High dose chemoradiotherapy with autologous hemotopoietic stem cell transplantation for treatment of patients with advanced Hodgkin's lymphoma: a report of 11 cases].
    Zhou SY; Shi YK; He XH; Han XH; Liu P; Yang JL; Zhou AP; Feng FY
    Ai Zheng; 2002 Apr; 21(4):405-8. PubMed ID: 12452021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma.
    Philip T; Armitage JO; Spitzer G; Chauvin F; Jagannath S; Cahn JY; Colombat P; Goldstone AH; Gorin NC; Flesh M
    N Engl J Med; 1987 Jun; 316(24):1493-8. PubMed ID: 3295541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patterns of failure of complete responders following high-dose chemotherapy and autologous bone marrow transplantation for metastatic breast cancer: implications for the use of adjuvant radiation therapy.
    Mundt AJ; Sibley GS; Williams S; Rubin SJ; Heimann R; Halpern H; Weichselbaum RR
    Int J Radiat Oncol Biol Phys; 1994 Aug; 30(1):151-60. PubMed ID: 8083108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Double high-dose therapy for Hodgkin's disease with dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP) prior to high-dose melphalan and autologous stem cell transplantation.
    Stewart DA; Guo D; Glück S; Morris D; Chaudhry A; deMetz C; Klassen J; Brown CB; Russell JA
    Bone Marrow Transplant; 2000 Aug; 26(4):383-8. PubMed ID: 10982284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mitoxantrone, vinblastine, and lomustine (CCNU) (MVC): a highly active regimen for advanced and poor-prognosis Hodgkin's disease.
    Wiernik PH; Dutcher JP; Einzig AI; Sparano J; Frank M; Friedenberg W
    Cancer J Sci Am; 1998; 4(4):254-60. PubMed ID: 9689984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma.
    Klumpp TR; Mangan KF; Glenn LD; Malaspina DR; Cropper T; Mullaney M; Macdonald JS
    Bone Marrow Transplant; 1993 Oct; 12(4):337-45. PubMed ID: 7506091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Refractory or relapsed Hodgkin's disease and non-Hodgkin's lymphoma: optimizing involved-field radiotherapy in transplant patients.
    Kahn ST; Flowers CR; Lechowicz MJ; Hollenbach K; Johnstone PA
    Cancer J; 2005; 11(5):425-31. PubMed ID: 16259874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: analysis of 280 patients from the French registry. Société Française de Greffe de Moëlle.
    Brice P; Bouabdallah R; Moreau P; Divine M; André M; Aoudjane M; Fleury J; Anglaret B; Baruchel A; Sensebe L; Colombat P
    Bone Marrow Transplant; 1997 Jul; 20(1):21-6. PubMed ID: 9232251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: a prognostic model for treatment outcomes.
    Wheeler C; Eickhoff C; Elias A; Ibrahim J; Ayash L; McCauley M; Mauch P; Schwartz G; Eder JP; Mazanet R; Ferrara J; Rimm IJ; Guinan E; Bierer B; Gilliland G; Churchill WH; Ault K; Parsons S; Antman K; Schnipper L; Tepler I; Gaynes L; Frei E; Kadin M; Antin J
    Biol Blood Marrow Transplant; 1997 Jun; 3(2):98-106. PubMed ID: 9267670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose chemotherapy and autologous peripheral blood progenitor cell transplant for the treatment of Hodgkin's disease.
    Weaver CH; Schwartzberg L; Li W; Hazelton B; West W
    Bone Marrow Transplant; 1996 May; 17(5):715-21. PubMed ID: 8733687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.